Literature DB >> 11031344

Elevated chemokine levels in bronchoalveolar lavage fluid of patients with eosinophilic pneumonia.

S Katoh1, N Matsumoto, K Fukushima, H Mukae, J I Kadota, S Kohno, S Matsukura.   

Abstract

BACKGROUND: Allergic lung inflammation is caused by accumulation and activation of different leukocyte subsets, such as eosinophils and T lymphocytes, in the lung. The chemokines are a large group of chemotactic cytokines that regulate leukocyte trafficking and may play an important role in allergic lung inflammation.
OBJECTIVE: The purpose of this study was to evaluate the role of various chemokines, including eotaxin, RANTES, monocyte chemotactic protein (MCP)-1, macrophage inflammatory protein (MIP)-1beta, and IL-8 in the pathogenesis of eosinophilic pneumonia (EP).
METHODS: The concentrations of eotaxin, RANTES, MCP-1, MIP-1beta, and IL-8 in bronchoalveolar lavage fluid (BALF) were measured by using ELISA in 15 patients with EP, 10 with idiopathic pulmonary fibrosis, 10 with sarcoidosis, and 11 healthy volunteers.
RESULTS: Eotaxin in BALF was high only in patients with EP, and its level correlated significantly with the number of eosinophils in BALF of patients with EP and healthy volunteers. MCP-1 and MIP-1beta in BALF were preferentially increased in patients with EP. There was a significant correlation between MCP-1 levels and the number of macrophages in BALF of patients with EP and healthy volunteers.
CONCLUSION: Our findings suggest that these CC chemokines contribute to the pathogenesis of EP through the specific recruitment of leukocyte subsets in the lung.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11031344     DOI: 10.1067/mai.2000.109827

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  8 in total

1.  Possible Role of IL-25 in Eosinophilic Lung Inflammation in Patients with Chronic Eosinophilic Pneumonia.

Authors:  Shigeki Katoh; Masaki Ikeda; Nobuhiro Matsumoto; Hiroki Shimizu; Masaaki Abe; Yoshihiro Ohue; Keiji Mouri; Yoshihiro Kobashi; Masamitsu Nakazato; Mikio Oka
Journal:  Lung       Date:  2017-09-05       Impact factor: 2.584

Review 2.  Eosinophilic pneumonias.

Authors:  Praveen Akuthota; Peter F Weller
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

3.  A possible role of galectin-9 in the pulmonary fibrosis of patients with interstitial pneumonia.

Authors:  Nobuhiro Matsumoto; Shigeki Katoh; Shigehisa Yanagi; Yasuji Arimura; Masatoshi Tokojima; Masaki Ueno; Mitsuomi Hirashima; Masamitsu Nakazato
Journal:  Lung       Date:  2013-01-16       Impact factor: 2.584

4.  MCP1 haplotypes associated with protection from pulmonary tuberculosis.

Authors:  Christopher D Intemann; Thorsten Thye; Birgit Förster; Ellis Owusu-Dabo; John Gyapong; Rolf D Horstmann; Christian G Meyer
Journal:  BMC Genet       Date:  2011-04-19       Impact factor: 2.797

5.  The relationship between the clinical course and cytokine in a patient with cigarette smoking-induced acute eosinophilic pneumonia - A case report.

Authors:  Yuta Kono; Kenji Tsushima; Koichi Yamaguchi; Seiko Soeda; Akahito Fujiwara; Shinya Sugiyama; Yuki Togashi; Satoshi Kasagi; Yasuhiro Setoguchi
Journal:  Respir Med Case Rep       Date:  2011-12-24

Review 6.  Possible Mechanisms of Eosinophil Accumulation in Eosinophilic Pneumonia.

Authors:  Kazuyuki Nakagome; Makoto Nagata
Journal:  Biomolecules       Date:  2020-04-21

7.  Dual RNA-Seq analysis of SARS-CoV-2 correlates specific human transcriptional response pathways directly to viral expression.

Authors:  Nathan D Maulding; Spencer Seiler; Alexander Pearson; Nicholas Kreusser; Joshua M Stuart
Journal:  Sci Rep       Date:  2022-01-25       Impact factor: 4.379

8.  p53/PUMA expression in human pulmonary fibroblasts mediates cell activation and migration in silicosis.

Authors:  Wei Wang; Haijun Liu; Xiaoniu Dai; Shencun Fang; Xingang Wang; Yingming Zhang; Honghong Yao; Xilong Zhang; Jie Chao
Journal:  Sci Rep       Date:  2015-11-18       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.